Luminal bacterial toxins and microbial products

Luminal bacterial toxins and microbial products represent a broad category of bioactive substances produced by the gastrointestinal microbiota or enteric pathogens, including endotoxins (lipopolysaccharides), exotoxins (e.g., Shiga toxin, Clostridioides difficile toxins A and B), and metabolic byproducts like indoxyl sulfate (PMID: 29415894, 31039171). These products are central to the pathophysiology of various conditions; for instance, C. difficile toxins TcdA and TcdB cause extensive mucosal damage and inflammation in the colon (PMID: 26827166). In chronic kidney disease, the accumulation of gut-derived uremic toxins contributes to systemic inflammation and cardiovascular complications (PMID: 26431134). Therapeutic intervention typically involves the use of oral adsorbents like AST-120 or bile acid sequestrants like cholestyramine, which bind these substances in the gut lumen to prevent their absorption or local toxic effects (PMID: 24833712). More targeted approaches include monoclonal antibodies, such as bezlotoxumab, which specifically neutralizes C. difficile toxin B to prevent infection recurrence (PMID: 28121507). Managing the toxin load in the lumen is a key approach in treating hepatic encephalopathy and slowing the progression of chronic kidney disease.

Other names

Gut-derived toxinsEnterotoxinsMicrobial metabolitesPathogen-associated molecular patternsPAMPsBacterial endotoxins

Sequestration and adsorption within the gastrointestinal lumen to prevent systemic absorption or local mucosal interaction; neutralization by specific antibodies.